Category - Developments

Developments

Hepion to present update on CRV431 nonclinical studies at NASH-TAG 2020 conference

Hepion Pharmaceuticals (NASDAQ:HEPA) is slated to present a poster at the upcoming NASH-TAG 2020 conference. The presentation will provide details of four nonclinical studies demonstrating that CRV431 decreases liver...

January 8, 2020

Developments

Imagin Medical successfully completes i/Blue’s design verification

Imagin Medical (CSE:IME; OTCQB:IMEXF; Frankfurt & Stuttgart Symbol:DPD2) completed design verification of its i/Blue Imaging System functional unit on schedule. i/Blue is based on advanced optics and light sensors...

January 8, 2020

Developments

Apellis reports positive topline Phase 3 data in paroxysmal nocturnal hemoglobinuria

Apellis Pharmaceuticals (NASDAQ:APLS) reported positive topline results from its Phase 3 study evaluating pegcetacoplan for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Pegcetacoplan met the study’s...

January 7, 2020

Developments

Hepion paper published in Expert Opinion on Investigational Drugs

Hepion Pharmaceuticals’ (NASDAQ:HEPA) comprehensive review of studies on the role of cyclophilins in non-alcoholic steatohepatitis (NASH) and NASH-related liver disease has been published in peer-reviewed journal...

January 6, 2020

Developments

X4 Pharma starts Phase 1b trial of mavorixafor for Waldenström’s macroglobulinemia

X4 Pharmaceuticals (NASDAQ:XFOR) initiated a Phase 1b trial of mavorixafor in combination with ibrutinib, a Burton tyrosine kinase (BTK) inhibitor, for the treatment of Waldenström’s macroglobulinemia (WM). WM is a rare...

December 30, 2019

Developments

Kate DeVarney joins Titan Pharma’s Board

Kate DeVarney, EVP and CSO of Titan Pharmaceuticals (NASDAQ:TTNP), was elected to the board at the company’s annual meeting. Dr. DeVarney, a clinical neuropsychologist by training, joined Titan in January...

December 30, 2019

Developments

Lexicon Pharmaceuticals’ reports topline Phase 3 data for Type 2 diabetes drug

Lexicon Pharmaceuticals (NASDAQ:LXRX) reported topline data from its Phase 3 study of sotagliflozin for the treatment of Type 2 diabetes (T2D). Sotagliflozin is an oral dual inhibitor of sodium-glucose co-transporter...

December 20, 2019

Developments

Aravive begins enrollment for Phase 2a kidney fibrosis trial

Aravive (NASDAQ:ARAV) has begun enrolling patients in its Phase 2a clinical trial of AVB-500 in patients with kidney fibrosis, specifically immunoglobulin A nephropathy (IgAN). IgAN occurs when an antibody called...

December 20, 2019

Developments

Arrowhead Pharma doses first patient in Phase 2 alpha-1 liver disease trial

Arrowhead Pharma (NASDAQ:ARWR) dosed the first patient in its Phase 2 clinical study of ARO-AAT for the treatment of alpha-1 antitrypsin deficiency (AATD)-associated liver disease. AATD is a rare genetic disorder where...

December 20, 2019

Developments

Concert Pharmaceuticals completes alopecia areata trial

Concert Pharmaceuticals (NASDAQ:CNCE) completed its open-label trial comparing once-daily versus twice-daily dosing of CTP-543 in alopecia areata patients. Alopecia areata is an autoimmune disease that causes partial or...

December 20, 2019

Category - Developments

Subscribe